You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Software as a Service Cardiovascular PACS Based on Web 2.0 Technologies
SBC: HEART IMAGING TECHNOLOGIES, LLC Topic: NHLBIDESCRIPTION (provided by applicant): Nearly two-thirds of all medical imaging procedures in the United States are performed in physician offices, yet few of these small healthcare providers can afford picture archiving and communication systems (PACS) needed to exchange these images with large hospitals. Without online access to previous imaging tests many procedures are repeated, leading to exces ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Stroke Treatment by Chemically-Induced Hypothermia
SBC: HALIMED PHARMACEUTICALS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the United States. In spite of intensive investigations, clinical therapies for treating acute stroke patients remain limited and unsatisfactory. There are consistent animal and human data that mild to moderate hypothermia (reducing body temperature to 32-34oC) is generally safe and improves outcome after brain ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 300DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
PBEF Neutralizing Humanized Monoclonal Antibodies As Novel Therapeutic Approaches
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIDESCRIPTION (provided by applicant): Approximately 40-60% of patients admitted to intensive care units (ICU) require mechanical ventilation with acute lung injury (ALI) a common diagnosis which mandates intubation and placement on the ventilator. It is nowwell recognized that the development of VILI directly contributes to the unacceptably high mortality rate associated with ALI and despite the ad ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Nitric Oxide Microfluidic Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDDESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors
SBC: NOVALEX THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A nanoparticle-based vaccine against leishmaniasis
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): We propose to develop a recombinant subunit vaccine against cutaneous leishmaniasis. This vaccine will incorporate two protein antigens, TSA/TryP and P-4. Both antigens are highly conserved among Leishmania species, arerecognized by T cells of human patients, and confer protection against a live challenge in murine model studies. We expect that immunization usi ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility
SBC: NOVALEX THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health